The FDA has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults.

“The approval of Bimzelx in moderate-to-severe hidradenitis suppurativa is welcome given the substantial unmet clinical needs and limited number of treatment options available today,” BE HEARD ...

The drug survival for adalimumab is significantly higher than that of infliximab in pediatric patients with hidradenitis suppurativa (HS), results from a small single-center study showed.

The drug survival for adalimumab is significantly higher than that of infliximab in pediatric patients with hidradenitis suppurativa, results from a small single-center study showed.in adults with HS ...

Fintel reports that on December 2, 2024, BTIG downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from Buy to Neutral.

CAN10 is designed to inhibit the pro-inflammatory cytokines through its action on the interleukin-1 receptor accessory ...

Medically reviewed by Susan Bard, MD An inner thigh rash is a skin irritation that develops on the inner portion of your ...

Cantargia's extraordinary general meeting on December 2, 2024, resolved to approve the board's resolution from November 6, ...

J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.

Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study to investigate higher dose levels of the antibody. The purpose of this ...